CytoDyn Transfers Research on Novel AIDS Drug to Massachusetts General Hospital

SANTA FE, N.M.--(BUSINESS WIRE)--In response to new economic and regulatory realities, CytoDyn, Inc. (Pink Sheets:CYDY) has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Studies of the drug will be designed and conducted by Massachusetts General Hospital, one of the premier teaching hospitals in Boston, Massachusetts, as part of its mission to advance medical knowledge and treatments through research, education and patient care.

Back to news